Abstract 1254P
Background
The Brain OMX diagnostic tool is designed to facilitate the analysis of both structural and functional connectivity of the brain using T1-weighted structural MRI (T1) and resting-state functional magnetic resonance imaging (rs-fMRI) data. This tool utilizes a retrospective approach to gain insights into the intricate workings of the brain and its underlying connections which also assist in various stages of surgical treatment needed in neurodegenerative diseases.
Methods
The Fast Surfer pipeline is designed to be computationally efficient, allowing for the rapid processing of large-scale MRI datasets. T1-weighted structural MRI provides detailed information about the anatomical features of the brain. Functional connectivity is measured by assessing the synchronization of the Blood Oxygenation Level Dependent (BOLD) signals between different brain regions.
Results
Auditory network, cingulate network, Default Mode network, DMN and Occipital network, Dorsal Attention network, Language network, Left attention network, Right Attention network, salience network, and visual network correlations are provided. Brain complexity, neurological disorders, and personalized treatment strategies can be achieved. The correlation matrix creates a comprehensive graph from RS-FMRI.
Table: 1254P
Structural analysis using BrainOMX
Subregion | Total | Left | Right | |||
Volume [cm3] | % ICV | Volume [cm3] | % ICV | Volume[cm3] | % ICV | |
Cortical white matter | 462.49 | 33.77% | 230.76 | 16.85 | 231.73 | 16.92 |
Thalamus | 13.97 | 1.02% | 7.11 | 0.52 | 6.85 | 0.50 |
Caudate | 6.13 | 0.45% | 2.96 | 0.22 | 3.17 | 0.23 |
Putamen | 9.46 | 0.69% | 4.72 | 0.34 | 4.74 | 0.35 |
Pallidum | 3.67 | 0.27% | 1.87 | 0.14 | 1.80 | 0.13 |
Hippocampus | 7.18 | 0.52% | 3.50 | 0.26 | 3.68 | 0.27 |
Amygdala | 2.71 | 0.20% | 1.36 | 0.10 | 1.35 | 0.10 |
Conclusions
By combining both structural and functional connectome analyses, the Brain OMX diagnostic tool aims to provide a comprehensive understanding of the brain's architecture for carcinomas and also its implications for neurological conditions. The tabulation shows Alzheimers neurodegenrative patient data, he connectivity can be the result of a direct anatomic connection or an indirect path via a mediating region or may have no known anatomic correlate. rs-fMRI is an imaging technique that plays a growing role in characterizing normal and abnormal functional brain connectivity in a variety of clinical conditions.
Clinical trial identification
Editorial acknowledgement
Data Acknowledgement:
1. Henschel L, Conjeti S, Estrada S, Diers K, Fischl B, Reuter M, FastSurfer - A fast and accurate deep learning based neuroimaging pipeline, NeuroImage 219 (2020), 117012. https://doi.org/10.1016/j.neuroimage.2020.117012
2. Henschel L*, Kügler D*, Reuter M. (*co-first). FastSurferVINN: Building Resolution-Independence into Deep Learning Segmentation Methods - A Solution for HighRes Brain MRI. NeuroImage 251 (2022), 118933. \\http://dx.doi.org/10.1016/j.neuroimage.2022.118933.
3. Zolotova, S. V., Golanov, A. V., Pronin, I. N., Dalechina, A. V., Nikolaeva, A. A., Belyashova, A. S., Usachev, D. Y., Kondrateva, E. A., Druzhinina, P. V., Shirokikh, B. N., Saparov, T. N., Belyaev, M. G., & Kurmukov, A. I. (2023). Burdenko’s Glioblastoma Progression Dataset (Burdenko-GBM-Progression) (Version 1) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/E1QP-D183
4. Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M., Tarbox, L., & Prior, F. (2013). The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository. In Journal of Digital Imaging (Vol. 26, Issue 6, pp. 1045–1057). Springer Science and Business Media LLC. \\https://doi.org/10.1007/s10278-013-9622-7
5. Semmineh, N. B., Stokes, A. M., Bell, L. C., Boxerman, J. L., & Quarles, C. C. (2020). GBM-DSC-MRI-DRO [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/TCIA.2020.RMWVZWIX
6. Semmineh, N. B., Stokes, A. M., Bell, L. C., Boxerman, J. L., & Quarles, C. C. (2017). A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials. In Tomography (Vol. 3, Issue 1, pp. 41–49). MDPI AG. \\https://doi.org/10.18383/j.tom.2016.00286
7. Kathleen M Schmainda, Melissa A Prah, Jennifer M Connelly, Scott D Rand. (2016). Glioma DSC-MRI Perfusion Data with Standard Imaging and ROIs [ Dataset ]. The Cancer Imaging Archive. \\DOI: 10.7937/K9/TCIA.2016.5DI84Js8
8. Schmainda KM, Prah MA, Rand SD, Liu Y, Logan B, Muzi M, Rane SD, Da X, Yen YF, Kalpathy-Cramer J, Chenevert TL, Hoff B, Ross B, Cao Y, Aryal MP, Erickson B, Korfiatis P, Dondlinger T, Bell L, Hu L, Kinahan PE, Quarles CC. (2018). Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. American Journal of Neuroradiology, 39(6), 1008–1016. DOI: 10.3174/ajnr.a5675
9.Barboriak, D. (2015). Data From RIDER NEURO MRI. The Cancer Imaging Archive. https://doi.org/10.7937/K9/TCIA.2015.VOSN3HN1.
10. Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M., Tarbox, L., & Prior, F. (2013). The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository. In Journal of Digital Imaging (Vol. 26, Issue 6, pp. 1045–1057). Springer Science and Business Media LLC. \\https://doi.org/10.1007/s10278-013-9622-7 PMCID: PMC3824915
Legal entity responsible for the study
PMX Inc., USA, and PMX, Seoul, Republic of Korea.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1774P - PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial
Presenter: Gabriela Ilie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1776P - Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Presenter: Martin Støyten
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1780P - The health inequality impact of darolutamide for non-metastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
Presenter: Jeroen Jansen
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14